Teva on track to sell generic Lotensin in the USA

17 November 2003

The US Food and Drug Administration has granted Israel's Tevatentative approval for benazepril hydrochloride tablets, 5mg, 10mg, 20mg and 40mg. The tablets are the AB-rated generic equivalent of Novartis' Lotensin, which has annual sales of about $333 million. Final approval is anticipated upon expiry of pediatric exclusivity, which protects the brand product until February 11, 2004. India's Ranbaxy has also been granted tentative approval to sell generic Lotensin.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight